OLD National Bancorp IN Acquires 7,066 Shares of Edwards Lifesciences Co. (NYSE:EW)

OLD National Bancorp IN raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 3.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 197,143 shares of the medical research company’s stock after acquiring an additional 7,066 shares during the period. OLD National Bancorp IN’s holdings in Edwards Lifesciences were worth $14,594,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in EW. Bowman & Co S.C. lifted its holdings in Edwards Lifesciences by 1.2% in the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after buying an additional 148 shares during the period. Mount Yale Investment Advisors LLC raised its holdings in shares of Edwards Lifesciences by 1.9% during the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after acquiring an additional 162 shares in the last quarter. JFS Wealth Advisors LLC lifted its stake in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares during the period. Seascape Capital Management boosted its holdings in Edwards Lifesciences by 0.5% in the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock valued at $2,177,000 after acquiring an additional 174 shares in the last quarter. Finally, Cooper Financial Group increased its position in shares of Edwards Lifesciences by 2.8% during the fourth quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after buying an additional 175 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE EW opened at $71.21 on Thursday. The company has a 50-day moving average price of $72.37 and a 200-day moving average price of $70.06. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $42.00 billion, a P/E ratio of 10.28, a PEG ratio of 3.54 and a beta of 1.11.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,000 shares of company stock valued at $2,195,180. Insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on EW. Citigroup increased their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Piper Sandler cut their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Barclays raised their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Finally, Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.